Studies on CIP caused by loss-of-function mutations in Nav1.7 and Nav1.7 knock-out mice models suggest that Nav1.7 is an ideal target for novel pain-relieving drugs. This evidence concerns the gene SCN9A and hereditary sensory and autonomic neuropathy.